Spots Global Cancer Trial Database for Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Official Title: Randomized Trial of Orathecin and Gemcitabine Versus Placebo and Gemcitabine in Patients With Non-Resectable Pancreatic Cancer Who Have Not Already Received Chemotherapy
Study ID: NCT00113256
Conditions
Interventions
Study Description
Brief Summary: Patients will be treated with gemcitabine and Orathecin (rubitecan) capsules to evaluate the current estimate of overall survival as a study endpoint prior to launching the blinded randomized phase (versus gemcitabine and placebo) of the study. Toxicity of the drug combination will also be evaluated.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Compassionate Cancer Care Medical Group, Corona, California, United States
11100 Warner Avenue, Ste. 200, Fountain Valley, California, United States
The Cancer Research & Prevention Center, Soquel, California, United States
Mile High Oncology, Denver, Colorado, United States
Norton Healthcare, Inc., Louisville, Kentucky, United States
Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States
Medical Oncology, Baton Rouge, Louisiana, United States
N. Mississippi Hematology & Oncology Associates, Tupelo, Mississippi, United States
Kansas City Cancer Center, Kansas City, Missouri, United States
Cancer Research of Long Island, Great Neck, New York, United States
Charleston Hematology Oncology, PA, Charleston, South Carolina, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
